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Abstract
Background: Recurrent heart failure (HF) events are common in patients discharged after acute decompensated heart failure
(ADHF). New patient-centered technologies are needed to aid in detecting HF decompensation. Transthoracic bioimpedance
noninvasively measures pulmonary fluid retention.
Objective: The objectives of our study were to (1) determine whether transthoracic bioimpedance can be measured daily with
a novel, noninvasive, wearable fluid accumulation vest (FAV) and transmitted using a mobile phone and (2) establish whether
an automated algorithm analyzing daily thoracic bioimpedance values would predict recurrent HF events.
Methods: We prospectively enrolled patients admitted for ADHF. Participants were trained to use a FAV–mobile phone dyad
and asked to transmit bioimpedance measurements for 45 consecutive days. We examined the performance of an algorithm
analyzing changes in transthoracic bioimpedance as a predictor of HF events (HF readmission, diuretic uptitration) over a 75-day
follow-up.
Results: We observed 64 HF events (18 HF readmissions and 46 diuretic uptitrations) in the 106 participants (67 years; 63.2%,
67/106, male; 48.1%, 51/106, with prior HF) who completed follow-up. History of HF was the only clinical or laboratory factor
related to recurrent HF events (P=.04). Among study participants with sufficient FAV data (n=57), an algorithm analyzing thoracic
bioimpedance showed 87% sensitivity (95% CI 82-92), 70% specificity (95% CI 68-72), and 72% accuracy (95% CI 70-74) for
identifying recurrent HF events.
Conclusions: Patients discharged after ADHF can measure and transmit daily transthoracic bioimpedance using a FAV–mobile
phone dyad. Algorithms analyzing thoracic bioimpedance may help identify patients at risk for recurrent HF events after hospital
discharge.
(JMIR Cardio 2017;1(1):e1)  doi: 10.2196/cardio.6057
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It is estimated that over 25 million people worldwide suffer
from heart failure (HF) [1,2]. Many patients with prior HF
experience episodes of acute decompensated heart failure
(ADHF) [3]. Both in Europe and in the United States, ADHF
is responsible for nearly 1 million hospitalizations annually,
and hospitalization rates from ADHF are increasing with the
aging population [4,5,6]. In fact, ADHF is now the leading cause
of hospital admissions among patients aged above 65 years in
the United States [7].
Contemporary HF management programs rely on active
surveillance for signs and symptoms of ADHF as well as
medication-related and disease-specific education to optimize
treatment. To date, these programs have shown only modest
success. This is, in part, because commonly used clinical
measures that include heart rate, blood pressure, and body
weight poorly identify individuals at risk for subsequent HF
events such as hospital admission [8,9]. There is, therefore, a
need to develop new monitoring technologies to augment
existing HF management programs. To be useful, these
technologies must detect ADHF at an early stage, be acceptable
to patients, facilitate communication between clinicians and
patients, and relate to near-term HF decompensation and
clinically relevant events.
Measures of thoracic bioimpedance, or opposition to an electric
current through thoracic tissues, can be used to identify
subclinical fluid retention [10]. Prior studies have demonstrated
that intrathoracic bioimpedance measured in HF patients with
implantable cardioverter-defibrillators (ICDs) predicts clinical
events, including ADHF and HF-related hospitalizations [10,11].
As few patients with HF are eligible for an ICD, a noninvasive,
user-friendly method for measuring thoracic bioimpedance
would be scalable to a much more generalizable, broader
population of patients. Small proof-of-concept studies have
shown that a wearable, investigational device can measure
thoracic bioimpedance, correlate with intrathoracic measures,
and predict intrathoracic volume retention [12,13,14]. We
designed the prospective SENTINEL-HF study to test the
following two hypotheses in a cohort of patients recently
discharged after hospitalization for ADHF: (1) Transthoracic
bioimpedance can be measured daily with a novel, noninvasive,
wearable fluid accumulation vest (FAV) and transmitted using
a mobile phone and (2) an automated algorithm analyzing daily
thoracic bioimpedance values would predict recurrent HF events.
Methods
Study Design and Setting
The rationale and design of the SENTINEL-HF study has
already been published [15]. In brief, SENTINEL-HF is a
prospective, nonrandomized, observational investigation
including survivors of an admission for ADHF with New York
Heart Association (NYHA) functional class II-IV HF. The final
study sample consisted of adult patients hospitalized for ADHF
at one of the 2 UMass-Memorial Medical Center (UMMMC)
campuses between June 2013 and April 2015. The UMMMC
serves a racially and sociodemographically diverse and elderly
HF population in Central MA [16,17]. The 30-day all-cause
readmission and death rates after a HF-related admission at
UMMMC (23% and 12%, respectively) are similar to US
national rates [18]. The study was approved by the Committee
for the Protection of Human Subjects in Research at the
University of Massachusetts Medical School (IRB H00001760)
and was registered as a clinical trial (Clinicaltrials.gov
NCT01877369).
FAV and Mobile Phone App Description
The FAV is a prototype, noninvasive wearable garment
manufactured by Philips Inc, and designed to measure
transthoracic bioimpedance from 4 reusable, embedded internal
textile electrodes (Figure 1). The FAV is sized for each
participant so that the electrodes rest snugly along the lower
lateral aspect of the thorax. Unpublished work carried out by
Philips Research before SENTINEL-HF has demonstrated
acceptable precision of repeated bioimpedance measures using
the FAV. An electronics module connected to the posterior
aspect of the FAV enables wireless communication with a paired
mobile phone app and determines transthoracic bioimpedance
at multiple frequencies, enabling a Cole model-based assessment
of intrathoracic fluid status [19]. The thoracic bioimpedance
measurements are facilitated with a specially designed HF app
running on an Android-based mobile phone (Figure 2). The
phone-based app guides users through the measurement steps,
controls measurement parameters, and transmits stored
bioimpedance values to a secure cloud server using encoded
GSM (Figure 2). The daily measurement routine requires an
average of 8-10 min to complete.
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Figure 1. Components of the FAV and ADHF detection strategy. Top: components of the FAV measurement system and the process for data acquisition,
transfer, and storage. Bottom: ADHF detection strategy. Depending on the presence of an alert, days are classified as TN or FP outside the detection
window, TN or TP within the detection window, and FN or TP within the critical window. FAV: fluid accumulation vest; ADHF: acute decompensated
heart failure; TN: true negative; TP: true positive; FN: false negative.
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Figure 2. Representative images from the SENTINEL- HF study app running on a study mobile phone.
Study Procedures
SENTINEL-HF’s data collection was focused on 3 main
activities (home monitoring using the FAV, participant
interviews, and clinical event tracking) that were initiated during
the index ADHF hospitalization and ended 75 days after hospital
discharge. Trained study staff abstracted all relevant clinical
information related to each subject’s index hospitalization,
including medical history, physical exam data, radiographic
findings, laboratory values, medications, as well as
demographics from the medical record.
Participant Recruitment
Patients with possible ADHF were identified using the hospitals’
electronic record by reviewing daily hospital admissions. Study
staff determined SENTINEL-HF eligibility based on a review
of admission diagnoses, chief complaint, and medical history.
Eligibility was confirmed using laboratory reports,
electrocardiographic data, and physical examination findings.
Adult, English-speaking patients (age ≥21 years) were
considered eligible for enrollment if they were admitted with a
primary diagnosis of ADHF or if they had 1 sign (eg, vascular
congestion on chest radiograph, any B-type natriuretic peptide
level >100 ng/l) and 1 symptom (eg, dyspnea, orthopnea)
consistent with ADHF. In addition, to ensure that only
symptomatic HF patients were included, we restricted our
inclusion to only those patients coded as having NYHA class
II or greater by their examining physician. Participants and their
caregivers also had to express a willingness to adhere to the
study protocol for 45 days after hospital discharge. Prisoners,
pregnant patients, patients with a permanent pacemaker or ICD,
patients with a known nickel or electrode allergy, patients
planning to move from their residence within 2 months of
enrollment, as well as patients with any of the following
diagnoses: end-stage renal disease requiring hemodialysis, home
oxygen-dependent chronic obstructive pulmonary disease, severe
primary pulmonary hypertension, severe psychiatric or
neurological disorders, advanced cancer, or a body habitus
preventing proper FAV electrode positioning, were considered
ineligible for SENTINEL-HF. Patients were approached during
their hospitalization and signed an informed consent.
Shortly before discharge, each enrolled participant was provided
his or her own personalized FAV monitoring kit. Study staff
demonstrated to participants (and their caregivers when possible)
how to wear the FAV and use the mobile phone to obtain a
measurement. Each mobile phone was programmed to
automatically load a user-friendly app (Figure 2) that initiated
an electronic handshake with the FAV, recorded a bioimpedance
measurement, and transmitted stored bioimpedance
measurements to a secure cloud-based server. After instruction,
participants were asked to demonstrate proper use of the mobile
phone and electronics module. They were provided a manual
of operations, a short form of instructions, a troubleshooting
guide, and a magnet with the study staff contact information.
Home Monitoring Protocol
During a 45-day home monitoring period, participants were
required to perform daily 5-min FAV measurements sitting
upright in a chair at a consistent time each morning. On
postdischarge day 1, the study staff called each participant to
answer questions related to the first FAV assessment. Participant
adherence was monitored on a daily basis and tracked based on
transmissions to the remote database. Study staff called
participants with 2 or more consecutive missed or nonevaluable
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measurements. If 2 subsequent missed days occurred after the
call, study staff visited the participant at home to troubleshoot
and provide a FAV self-assessment walk-through. As shown
in Figure 3 participants were removed from the study if 2
consecutive missed days occurred after the home visit.
Figure 3. Participant flow diagram for the SENTINEL-HF study.
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Participants were interviewed in person or over the telephone
at enrollment (as an inpatient) and at days 7, 14, and 45 after
discharge. During these follow-up interactions, key patient
reported outcomes were assessed. Validated instruments
included the Kansas City Cardiomyopathy Questionnaire
(KCCQ) [20] and the Telephone Interview for Cognitive Status
(TICS) [21]. Participants were also asked about medication
changes, health care visits, or hospital readmissions. Reports
were confirmed by reviewing the medical record.
Study Outcomes and Endpoint Adjudication
This study assessed the ability of an automated algorithm that
evaluated daily transthoracic bioimpedance measures to predict
a composite endpoint of unplanned, HF-related rehospitalization
or diuretic uptitration over a total of 75 days following hospital
discharge. Endpoints were adjudicated on a rolling basis by 3
physicians (TEM, DDM, and CD) blinded to FAV measures
and clinical outcomes. FAV measures were not used for clinical
management, as this was an observational study.
Passive surveillance for study endpoints after hospital discharge
was carried out by review of clinical data, including hospital
visits, clinic notes, cardiac studies, laboratory reports, operative
reports, consultations, and hospital discharge summaries. As
most (>80%) patients hospitalized for ADHF at UMMMC
follow-up with a UMMMC cardiologist and are readmitted at
UMMMC, the vast majority of participant data was available
in one centralized electronic medical record. Information related
to patient-reported clinical events occurring outside our hospital
system was obtained from the respective health care providers
or from the outside medical record.
HF Decompensation Detection Algorithm
The ADHF detection algorithm is tailored to each patient, and
it monitors the daily evolution of transthoracic bioimpedance
index (Figure 4). Specifically, the algorithm classifies every
impedance measurement as “normal” or “abnormal” using an
adaptive range around the expected normal bioimpedance for
the patient. The ”normal” range for a given patient is established
over the first 4 days after discharge using the patient’s initial
measurements and knowledge from prior studies about the
normal variability of the bioimpedance index in ambulatory,
asymptomatic HF patients. [17,22,23]. The algorithm raises a
HF alert if it notes a sustained reduction in bioimpedance index,
as determined by 3 consecutive days of bioimpedance values
below the patient-specific normal range. Therefore, the earliest
possible HF alert occurred on day 7 after discharge.
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Figure 4. Cumulative clinical HF events over the 75-day follow-up period. Red line = Diuretic up-titrations, Blue Line = HF Rehospitalizations. FAV
learning period = first 6 days, FAV monitoring period = next 39 days. Total surveillance period = 75 days. HF: heart failure; FAV = fluid accumulation
vest.
Data Analysis
Our study sample was divided into 2 groups for analysis: (1)
participants with a clinically relevant recurrent HF event
(HF-related readmission or diuretic uptitration) during the
75-day follow-up period; and (2) participants without clinical
HF events. To compare participants with and without events,
we calculated frequencies and percentages for nominal
categorical variables, means and standard deviations for
continuous variables, and mean and interquartile ranges for
ordinal variables, for all patients and for each of the 2 groups
separately. We compared differences between the 2 groups by
using the chi-square test for nominal categorical variables with
cell size ≥5 and Fisher exact test for variables with small cell
size (<5). Differences in means between the 2 groups were
compared using t test and nonparametric Wilcoxon test. The
Wilcoxon test was also used to compare differences in medians
between ordinal variables. A P value of <.05 was considered
significant.
To analyze the performance of the automated HF detection
algorithm, we restricted our analysis to subjects with sufficient
usable bioimpedance data (defined as ≥65% analyzable, daily
bioimpedance measurements). We first compared the
characteristics of participants with and without usable
bioimpedance data using the methods described above. We then
examined the predictive ability of the FAV by calculating
sensitivity, specificity, and accuracy of the HF detection
algorithm with the following definitions and assumptions: First,
fluid accumulation due to worsening HF may begin several days
to weeks before a clinically apparent HF event. We defined the
time window between the period when a decompensation event
begins and the occurrence of a clinically apparent HF event as
the detection window. We then defined the 3 days before any
HF event as the critical window. We set the critical window at
3 days based on two assumptions: (1) fluid accumulation leading
to a HF decompensation would be highly likely to be present
during this period, and (2) 3 days would provide the minimum
actionable period for a clinician to receive an alert and act on
it (Figure 1).
Each monitoring day was then classified as a true positive (TP),
true negative (TN), false positive (FP), or false negative (FN).
We considered a TP any day when an alert was present and
preceded a HF event within a 30-day detection window. Any
day with an alert raised outside the 30-day detection window
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was considered an FP. Each day without an alert outside the
critical window was considered a TN. Finally, all days without
an alert but within the critical window were considered FNs
(Figure 1). A sensitivity analysis was carried out by varying the
lengths of the critical window from 3 to 14 days and the
detection window from 14 to 30 days. All analyses were




Of the 180 participants who consented to participate in
SENTINEL-HF, 106 completed the 75-day follow-up period
(Figure 3). Patient request to leave the study (n=45), for a variety
of reasons, was the most common cause for early dropout. As
shown in Table 1, the average age of study participants was 67
years, 63% were male, and 91% were white. The burden of
comorbid cardiovascular risk factors and diseases was high,
disorders of cognition were present in nearly a third of patients,
and HF symptom severity was modest. Of the 106 participants
who completed follow-up, participants with a history of HF
(P<.05) were more likely to have a recurrent HF event than
were patients without known HF at the time of their ADHF
admission. Notably, length of index hospital stay, peak
B-natriuretic peptide level, left ventricular systolic function,
and age were not related to hospital readmission within 75 days.
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.5266.4 (12.0)67.7 (10.7)67.2 (11.2)Age (years), mean (SD)b
.5330 (67)37 (61)67 (63.2)Male, n (%)
.0638 (84)58 (95)96 (90.6)Race (white), n (%)
.4833.4 (7.0)32.5 (8.0)32.9 (7.6)Body mass index (kg/m2), mean (SD)
.8544.1 (19.1)43.6 (18.0)44.0 (18.3)Left ventricular Ejection fraction, mean
(SD)
.193 (2-4)3 (2-4)3 (2-4)NYHA classc, median (IQR)b
Index admission, mean (SD)
.66708.0 (472.8)980.41 (938.9)864.0 (782.7)BNPd, ng/dL
.071.4 (0.7)1.2 (0.5)1.2 (0.6)Serum creatinine (mg/dL)
.85136.4 (3. 6)136.4 (3.4)136.0 (3.4)Serum sodium (mg/dL)
.77135.4 (25.54)135.7 (28.2)136.0 (27.0)Systolic blood pressure
(mmHg)
.2977.0 (22.3)79.9 (17.9)79.0 (19.9)Diastolic blood pressure
(mmHg)
.3589.0 (25.1)93.3 (24.1)91.0 (24.5)Heart rate (beats/min)
.5720.3 (3.7)20.1 (4.6)20.0 (4.2)Respiratory rate (breaths/min)
.8543.9 (26.8)45.1 (25.8)45.0 (26.1)KCCQe total symptom score
.0831 (4.9)32.6 (3.5)32.0 (4.2)TICSf total score
Hospital characteristics, mean (SD)
.535 (3.1)5.5 (3.6)4.0 (3.7)Hospital length of stay (days)
Medical history, n (%)
.2012 (27)10 (16)22 (20.7)Myocardial infarction
.1410 (22)7 (11)17 (16.0)Coronary artery bypass
.5935 (78)50 (82)85 (80.2)Hypertension
.641 (2)3 (5)4 (3.8)Stroke
.0427 (60)24 (39)51 (48.1)Heart failure
.1524 (53)24 (39)48 (5.2)Diabetes mellitus
.5621 (47)32 (52)53 (50.0)Hypercholesterolemia
.729 (20)14 (23)23 (21.7)Chronic lung disease
.368 (18)7 (11)15 (14.1)Renal failure
.2618 (40)18 (30)36 (33.9)Atrial fibrillation
Home medications, n (%)
.5938 (84)49 (80)87 (82.1)Beta blockers
.1323 (51)40 (66)63 (59.4)ACEg-inhibitors
.3738 (84)55 (90)93 (87.7)Diuretics
.585 (11)9 (15)14 (13.2)Digoxin
aP value compares the subgroups with HF events (HF rehospitalization or diuretic uptitration).
bData are expressed as mean (SD) for continuous variables, and median (IQR) for ordinal variables. Counts are reported as percentage of the respective
subgroup.
cNYHA: New York Heart Association.
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dBNP: B-type natriuretic peptide.
eKCCQ: Kansas City Cardiomyopathy Questionnaire.
fTICS: telephone interview for cognitive status.
gACE: Angiotensin-converting enzyme.
Figure 5. Daily bioimpedance values, HF alerts, and recurrent HF events from a representative SENTINEL-HF participant. Serial bioimpedance
measurements (circles) in a SENTINEL-HF participant with 2 clinical HF events (gold lines). This participant experienced a decrease in bioimpedance
starting 1 week after hospital discharge. The participant’s diuretic dose was increased twice (vertical lines) due to increased edema and bioimpedance
measures returned toward the baseline. The red dots indicate daily FAV alerts. HF: heart failure; FAV = fluid accumulation vest.
Data Acquisition and Protocol Adherence
When supported by the study staff, approximately half (n=87)
of the 180 consenting participants transmitted usable
bioimpedance measures on over 65% of days during the 45-day
follow-up. The major reason for study withdrawal was
nonadherence to scheduled FAV uploads for >2 consecutive
days. In addition to patient-initiated study withdrawal, technical
factors, including motion and noise artifact, or mobile phone
app malfunction, contributed to the data loss (n=30). This left
57 participants (53.8%), with sufficient bioimpedance data for
the automated HF detection algorithm to analyze (Figure 3).
The characteristics of the SENTINEL-HF participants with
adequate interpretable data did not vary significantly from those
who did not have sufficient data, with the exception of a slightly
longer index hospital stay observed among patients with lower
adherence to the FAV (Table 2).
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.7767.65 (12.7)66.8 (9.9)67.2 (11.2)Age (years), mean (SD)b
.4133 (67)34 (60)67 (63.2)Male, n (%)
.6845 (92)51 (89)96 (90.6)Race (white), n (%)
.2234.0 (8.4)32.0 (6.7)32.9 (7.6)Body mass index (kg/m2), mean (SD)
.9443.5 (17.8)44.1 (19.0)44.0 (18.3)LV ejection fraction, mean (SD)
.713 (2-3)3 (2-4)3 (2-4)NYHAc class, median (IQR)b
Index admission, mean (SD)
.48712.5 (465.5)997 (967)864.0 (782.7)BNPd (ng/dL)
.241.3 (0.7)1.2 (0.5)1.2 (0.6)Serum creatinine (mg/dL)
.68136.0 (4.1)137 (2.8)136.0 (3.4)Serum sodium (mg/dL)
.60136.0 (24.3)135.3 (29.3)136.0 (27.0)Systolic blood pressure (mmHg)
.7378.5 (19.7)78.8 (20.2)79.0 (19.9)Diastolic blood pressure (mmHg)
.8192.5 (26.6)90.5 (22.9)91.0 (24.5)Heart rate (beats/min)
.2220.3 (3.1)20.1 (5.0)20.0 (4.2)Respiratory rate (breaths/min)
.0739.3 (25.2)49.0 (26.2)45.0 (26.1)KCCQe total symptom score
.7131.6 (4.8)32.2 (3.6)32.0 (4.2)TICSf total score
Outcome, n (%)
.388 (16)6 (11)14 (13.2)HF readmission over 75 days
.0721 (43)15 (26)36 (33.9)Diuretic uptitration over 75 days
Medical history, n (%)
.9410 (20)12 (21)22 (20.7)Myocardial infarction
.2610 (20)7 (12)17 (16.0)Coronary artery bypass
.8939 (80)46 (81)85 (80.2)Hypertension
.243 (6)1 (2)4 (3.8)Stroke
.8724 (49)27 (47)51 (48.1)Heart failure
.7523 (47)25 (44)48 (5.2)Diabetes mellitus
.0820 (41)33 (58)53 (50.0)Hypercholesterolemia
.5212 (25)11 (19)23 (21.7)Chronic lung disease
.558 (16)7 (12)15 (14.1)Renal failure
.0721 (43)15 (26)36 (33.9)Atrial fibrillation
Home medications, n (%)
.9140 (82)47 (82)87 (82.1)Beta blockers
.6628 (57)35(61)63 (59.4)ACEg-inhibitors
.5544 (90)49 (86)93 (87.7)Diuretics
.767 (14)7(12)14 (13.2)Digoxin
aP value compares the subgroups with HF events (HF rehospitalization or diuretic uptitration).
bData are expressed as mean (standard deviation) for continuous variables, and median (interquartile range) for ordinal variables. Counts are reported
as percentage of the respective subgroup.
cNYHA: New York Heart Association.
dBNP: B-type natriuretic peptide.
eKCCQ: Kansas City Cardiomyopathy Questionnaire.
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fTICS: telephone interview for cognitive status.
gACE: Angiotensin-converting enzyme.
Study Endpoints
Among the 57 participants with ADHF who were included in
our analysis of the HF detection algorithm, we observed 25 HF
events in 20 patients over a 75-day follow-up. HF events
included 8 HF-related hospital readmissions and 17 diuretic
uptitrations. HF events were evenly distributed throughout the
75-day follow-up period (Figure 4).
The mean time between a bioimpedance-based HF alert and a
clinical HF event was 21 days (median 11 days). Figure 5
illustrates a representative participant’s daily bioimpedance and
the relationship among impedance changes, HF alerts, and HF
events. The automated HF prediction algorithm exhibited
reasonable sensitivity but modest specificity for prediction HF
events within the 30 days of an alert with a sensitivity of 87%
(95% CI 82-92), specificity of 70% (95% CI 68-72), and
accuracy of 72% (95% CI 70-74; Table 3). A sensitivity analysis
(Table 3) examining the effect of varying the detection window
and critical window showed that shortening the detection
window from 30 days or expanding the critical window beyond
3 days reduced the predictive performance of the automated HF
detection algorithm.
Table 3. Sensitivity analysis for fluid accumulation vest (FAV) performance.












The results of this prospective, observational study demonstrate
that older patients recently discharged after a HF event can
measure and transmit transthoracic bioimpedance daily using
a novel vest–mobile phone system. Our findings also show that
an automated algorithm analyzing transthoracic bioimpedance
was able to detect HF decompensation with reasonable
sensitivity before clinical HF events. Automated bioimpedance
measurement and analysis is possible using mobile technologies
and may provide an innovative mechanism to monitor HF
patients and improve their care.
As patients who have had a recent HF-related hospitalization
are known to be at high risk for recurrent HF decompensation
and readmission after discharge [22], we recruited participants
admitted with ADHF. Readmissions after a HF hospitalization
are often considered preventable and reflective of poor
in-hospital management or discharge practices [3]. In recent
years, the Patient Protection and Affordable Care Act established
payment reforms that penalize US hospitals with high
readmission rates following a HF-related hospitalization [24].
HF admissions are associated with great personal cost to the
patient and economic costs to our health care system [25,26],
and readmission penalties have heightened interest in developing
innovative HF management programs. As traditional physical
exam findings have been found to be unreliable predictors of
ADHF in patients with chronic HF [27], novel technologies are
needed to help identify HF decompensation. Moreover,
monitoring patients with HF at home is vital as it has been
demonstrated that ambulatory HF patients need guidance in
order to seek care in a timely fashion [27-29].
The FAV is designed to measure thoracic bioimpedance, which
varies with the patient-specific fluid volume. Several studies
have associated thoracic fluid accumulation, with HF
decompensation. These measures compare favorably with
clinical HF metrics such as weight gain [30-33]. In the
SENSE-HF trial, a study of 501 ambulatory patients with
chronic HF [34] and an ICD, intrathoracic bioimpedance
exhibited modest sensitivity (up to 42%) for predicting
HF-related readmissions. Although some efforts to use
continuous bioimpedance values coupled with patient-agnostic
cut-offs for determining abnormal values have exhibited
suboptimal accuracy [34], recent studies have demonstrated that
more sophisticated approaches improve the performance of
automated algorithms analyzing bioimpedance [30-33]. On this
basis, many clinical HF programs use intrathoracic
bioimpedance to guide therapeutic decision making in
ambulatory patients with chronic HF and implantable
defibrillators [35,36]. Although bioimpedance assessment using
implantable devices is helpful for many HF patients with
severely reduced systolic dysfunction, the majority of HF
patients do not have them.
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Therefore, we tested a new approach using a wearable device
paired to a mobile phone to monitor thoracic bioimpedance as
such systems have shown promise in preliminary studies [12]
and would be potentially usable by a more diverse and larger
number of ambulatory patients with HF. Moreover, we also
sought to improve on existing analytic approaches by training
our algorithm to familiarize itself with a patient-specific normal
bioimpedance range.
Overall, when supported through in home visits and phone
instructions, about half of the study participants transmitted
usable bioimpedance measures on over 65% of study days
during the postdischarge period. Participants were able to
achieve a reasonable adherence rate to this intensive program
despite being older, symptomatic, and having a modest burden
of psychosocial and cognitive impairments. We had to withdraw
49 participants (Table 2) from the study primarily due to
nonadherence to scheduled uploads. Only 30 participants had
data that were deemed “nonusable,” and the proportion of
individuals with nonusable data decreased over time, as several
factors such as motion and noise artifact or mobile phone FAV
pairing errors (ie, not syncing or defaulting to airplane mode)
were identified and corrected by study engineers and staff who
reviewed data on a daily basis. We observed that daily review
of uploads was helpful to improve data quality and target
participants struggling with device use. Other studies have had
similar adherence issues to telemonitoring with ranges of
adherence between 4% and 55% withdrawing after enrollment
[37]. Although we did not observe significant differences
between study participants excluded for nonadherence and those
who were able to adhere to FAV use, further research is needed
to investigate factors associated with adherence to enable ideal
targeting of this monitoring strategy.
Clinical HF recurrence was common in our cohort but consistent
with rates reported in prior studies of patients hospitalized for
ADHF [17]. Despite the aforementioned loss of some device
data due to corruption or loss of transmission, our automated
algorithm analyzing transmitted thoracic bioimpedance values
demonstrated reasonable performance as a screening test for
participants with usable data, with a sensitivity of 87%,
specificity of 70%, and an overall accuracy of 72%. In a prior
study including 33 patients with NYHA class III-IV HF who
underwent implantation of a HF monitoring device and were
followed for a mean 21 (SD 8) months, intrathoracic
bioimpedance correlated strongly and inversely with pulmonary
capillary wedge pressure and net fluid loss. In this same study,
automated detection of decreased intrathoracic impedance
showed somewhat lower sensitivity (77%) for predicting
rehospitalizaton for HF compared with that observed in our
study [38]. In another study including 43 older, ambulatory HF
patients with an ICD capable of intrathoracic bioimpedance
measurement, and followed over an average of 220 days for
worsening HF (as defined by hospitalization or signs or
symptoms of HF), changes in bioimpedance had a positive
predictive value of 78.6% [39]. Finally, the SENSE-HF trial
showed in 501 older participants with HF and an ICD capable
of intrathoracic bioimpedance measurement that sensitivity was
low during the 6 months after device implant, but improved 6
months after implantation [34]. In sum, our results suggest that
transthoracic bioimpedance-based HF decompensation detection
shows similar performance to automated intrathoracic
biompedance-based approaches [10,34,39].
As exhibited by our sensitivity analyses, the HF detection
algorithm performance varied when the duration of the detection
window or critical window were altered. Our sensitivity analysis
also highlights an important aspect of any bioimpedance
telemonitoring system for HF patients. Our data suggests that
individual patterns of bioimpedance variability exist, and
therefore in the days leading up to a HF decompensation alerts
may be constant or unpredictable and intermittent. Therefore,
setting “rules” for how a bioimpedance algorithm would be
expected to perform in a heterogenous group of patients is
difficult, and further study and refinement of the detection
algorithm may lead to greater accuracy. With additional
optimization, FAV measurements may provide key data as part
of an overall home care system that monitors a range of
objective (eg, changes in weight and vital signs) and subjective
factors (eg, HF symptoms).
A variety of systems have been put in place to support patients
with HF in the outpatient setting [8,40]. These programs
typically serve the dual function of supporting the patient with
HF at home so they can better manage their HF, and secondarily
they seek to monitor the clinical status of each patient [41,42].
However, monitoring for signs and symptoms of HF, including
analyses of symptom scores, blood pressure, heart rate, and
weight, perform poorly as predictors of clinically relevant HF
events [3,42]. Following daily thoracic bioimpedance might
augment such systems by providing a more specific measure
of intrathoracic fluid.
As many wearables, including the FAV, collect
electrocardiographic and respiratory data, in addition to
bioimpedance [43], we anticipate that bioimpedance analysis
will ultimately be integrated into a multiparameter HF
monitoring approach. We also expect that our mobile phone
app might be enhanced to enable daily symptom assessment or
documentation of medication usage. We envision that
implementation of the FAV-mobile phone monitoring system
in a clinical system should occur in the context of a
comprehensive HF management program, be guided by HF
specialists, and be targeted at patients with recurrent HF
admissions who are not ICD candidates. Comprehensive HF
programs have the advantage of longitudinal relationships with
HF patients that extend beyond inpatient service lines and into
the clinic, expertise monitoring HF patients for decompensation
using bioimpedance, and knowledge needed to guide therapeutic
changes to improve quality of life and reduce HF readmissions,
and thus are well-suited to perform transthoracic bioimpedance
monitoring using existing infrastructure.
Study Strengths and Limitations
There are several strengths of this study. First, it included the
enrollment of a generalizable, older cohort of participants with
ADHF and multiple psychosocial, cognitive, and cardiovascular
comorbidities. Second, our study utilized rigorous and blinded
adjudication of clinically relevant HF events. A third strength
was our use of validated patient-reported assessments to
phenotype study participants vis-a-vis their cognitive status,
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psychosocial characteristics, and symptom-burden. However,
several limitations should be considered when interpreting the
results of this study. First, the overall sample size was modest
due to data loss and patient withdrawal. A prespecified interim
analysis for sample size reassessment revealed that technical
factors, including motion and noise artifact and mobile phone
app malfunction, contributed to data loss. To help mitigate this,
we implemented a feedback loop to assess measurement quality
and recommend corrective actions, which enhanced the amount
of interpretable data. Notably, participants included in the HF
detection algorithm analysis did not differ significantly from
participants without sufficient interpretable data, enhancing
generalizability. Second, our specificity was affected by FPs.
The FP rate is influenced by many factors including the time
interval considered relevant for tracking bioimpedance before
a HF event. We chose to have patients only do a single daily
measurement, but taking additional measures may have
decreased the FP rate. The other factor affecting FPs relates to
the target sensitivity of the FAV system. If a lower sensitivity
was targeted, the specificity would have risen at the expense of
missed HF exacerbations that may be unacceptable. Third, our
cohort was racially homogenous and from a single US region.
The generalizability of our findings to other racial and ethnic
groups with HF is therefore unclear. Finally, FAV support by
the study staff might limit our generalizability to situations
where inhome or telephone support may not be feasible.
Nevertheless, our approach was not greatly different from some
intensive clinical HF monitoring programs and may provide a
blueprint for future clinical HF programs that incorporate novel
technologies for HF assessment.
Conclusions
We observed that an automated algorithm analyzing daily
bioimpedance uploads from a FAV–mobile phone dyad
predicted clinically relevant HF recurrences in a cohort of older
survivors of an ADHF-related hospitalization, who were
followed for 75 days postdischarge. We are heartened by these
findings but recognize that enhancements are needed to improve
the percentage of usable bioimpedance data, perhaps through
real-time analysis and feedback to participants with noisy or
uninterpretable data uploads. Future clinical trials should focus
on enhancing the accuracy of ADHF prediction by assessing
additional parameters of cardiovascular health and should
evaluate whether bioimpedance-informed therapeutic decisions
reduce HF events. We are optimistic that mobile HF monitoring
solutions such as ours will ultimately improve the prognosis
and quality of life of ambulatory patients with chronic HF.
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